2026 Q3 - tulosraportti
UUTTA
6 päivää sitten
‧48 min
2,35 DKK/osake
Viimeisin osinko
1,45%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 000 | ||
| 395 | ||
| 120 | ||
| 30 | ||
| 1 994 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·9 t sitten · MuokattuThere is a price potential of a full 30 % if the analysts are right......So hold on to your shares - we are going much higher up....... Novonesis target price raised after interim report 6 Nov. 07:46 ∙ News overview (AI) The Danish biotech company Novonesis (Novozymes) B experienced an increase in the share price following the publication of the company's latest interim report. In response to the financial results, a number of leading financial institutions have upgraded their target prices for the company. These widespread adjustments reflect strong analyst confidence, and several prominent banks reiterate positive recommendations such as 'Buy' or 'Overweight'. Novonesis (Novozymes) B shares rose 3 % on Nasdaq Copenhagen following the publication of the company's interim report. SEB and Nordea set the highest new target prices at respectively 580 DKK (up from 560 DKK) and 575 DKK (up from 540 DKK), and both maintain the 'Buy' recommendation. Barclays raised its target price to 510 DKK (from 500 DKK) with an 'Overweight' recommendation, while Danske Bank raised its target price to 465 DKK (from 455 DKK) with a 'Hold' recommendation. BNP Paribas raised its target price to 455 DKK (from 420 DKK) and maintains a 'Neutral' recommendation.
The share price of Novonesis is not only lagging significantly behind the price of Givaudan. Compared to other peers such as DSM and Symrise, Novonesis also has a massive lag.
1 päivä sittenUnfortunate slump the last week. Was hoping that this would be a beneficiary of potential AI sector rotation
It will probably come back up, but it is a bit calmer than average, though it is way down now. However, it is a biotech stock whose potential for development is quite large with many branches out as well as acquisitions of small fry.- ·1 päivä sittenGivaudan has delivered a reasonable return this year, both on share price and exchange rate. The price relation to Novonesis is interesting today. Rarely has the relative price of Novonesis been this low. Have therefore shifted Givaudan to Novonesis.
- ·6.11.Geopolitics is making customers seek other solutions, says Novonesis CFO Close today at 10:01 ∙ MarketWire Novonesis (Novozymes) B 4,51% Sky-high oil prices due to geopolitical unrest are causing many countries to seek alternative energy sources. And Novonesis plays a role here, as the group supplies enzymes used to make bioethanol. "We have not seen the big picture change in relation to our Bioenergy division. The activity level has increased - especially in emerging markets," says Novonesis CFO Rainer Lehmann to MarketWire. Here, the CFO specifically points to Asian countries, highlighting India, Indonesia, and Vietnam as drivers. Looking at total revenue in Asia Pacific in July, August, and September, it rose to 206.5 million euros compared to 193.4 million euros in the 2025 quarter. Emerging markets overall accounted for revenue of 437.3 million euros, up from 404.2 million euros in the third quarter of last year. DOUBLE-DIGIT GROWTH RATES IN ENERGY In the financial report, Novonesis writes that the energy division alone "was driven by double-digit growth in energy across most regions, reflecting increased production and adoption of solutions for ethanol and biodiesel." "We see that energy security is a theme. That people are pursuing sources other than oil. We have seen, among other things, that the blending ratio in fuel is shifting in many countries," says Rainer Lehmann. It is a matter of how much bioethanol is blended into regular fuel. For example, looking at the US, the sale of gasoline with a higher bioethanol content, E15, has been opened for the entire year this year. And Novonesis, which sells enzymes to American farmers for precisely ethanol production, is in the race to get farmers to choose the Danish company's enzymes for production. The proposal for permanent permission for nationwide year-round sales is to be voted on after the midterm elections. According to Haider Anjum, senior analyst at Jyske Bank, a potential expansion of E15 in the US is not yet factored into the group's long-term plans. He points out that it will be additional upside for sales. .\˙ MarketWire
- 5.11.Good earnings as expected
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 65 025 | 65 025 | 0 | 65 025 |
| Anonyymi | 569 822 | 569 822 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 65 025 | 65 025 | 0 | 65 025 |
| Anonyymi | 569 822 | 569 822 | 0 | 0 |
2026 Q3 - tulosraportti
UUTTA
6 päivää sitten
‧48 min
2,35 DKK/osake
Viimeisin osinko
1,45%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·9 t sitten · MuokattuThere is a price potential of a full 30 % if the analysts are right......So hold on to your shares - we are going much higher up....... Novonesis target price raised after interim report 6 Nov. 07:46 ∙ News overview (AI) The Danish biotech company Novonesis (Novozymes) B experienced an increase in the share price following the publication of the company's latest interim report. In response to the financial results, a number of leading financial institutions have upgraded their target prices for the company. These widespread adjustments reflect strong analyst confidence, and several prominent banks reiterate positive recommendations such as 'Buy' or 'Overweight'. Novonesis (Novozymes) B shares rose 3 % on Nasdaq Copenhagen following the publication of the company's interim report. SEB and Nordea set the highest new target prices at respectively 580 DKK (up from 560 DKK) and 575 DKK (up from 540 DKK), and both maintain the 'Buy' recommendation. Barclays raised its target price to 510 DKK (from 500 DKK) with an 'Overweight' recommendation, while Danske Bank raised its target price to 465 DKK (from 455 DKK) with a 'Hold' recommendation. BNP Paribas raised its target price to 455 DKK (from 420 DKK) and maintains a 'Neutral' recommendation.The share price of Novonesis is not only lagging significantly behind the price of Givaudan. Compared to other peers such as DSM and Symrise, Novonesis also has a massive lag.
- 1 päivä sittenUnfortunate slump the last week. Was hoping that this would be a beneficiary of potential AI sector rotationIt will probably come back up, but it is a bit calmer than average, though it is way down now. However, it is a biotech stock whose potential for development is quite large with many branches out as well as acquisitions of small fry.
- ·1 päivä sittenGivaudan has delivered a reasonable return this year, both on share price and exchange rate. The price relation to Novonesis is interesting today. Rarely has the relative price of Novonesis been this low. Have therefore shifted Givaudan to Novonesis.
- ·6.11.Geopolitics is making customers seek other solutions, says Novonesis CFO Close today at 10:01 ∙ MarketWire Novonesis (Novozymes) B 4,51% Sky-high oil prices due to geopolitical unrest are causing many countries to seek alternative energy sources. And Novonesis plays a role here, as the group supplies enzymes used to make bioethanol. "We have not seen the big picture change in relation to our Bioenergy division. The activity level has increased - especially in emerging markets," says Novonesis CFO Rainer Lehmann to MarketWire. Here, the CFO specifically points to Asian countries, highlighting India, Indonesia, and Vietnam as drivers. Looking at total revenue in Asia Pacific in July, August, and September, it rose to 206.5 million euros compared to 193.4 million euros in the 2025 quarter. Emerging markets overall accounted for revenue of 437.3 million euros, up from 404.2 million euros in the third quarter of last year. DOUBLE-DIGIT GROWTH RATES IN ENERGY In the financial report, Novonesis writes that the energy division alone "was driven by double-digit growth in energy across most regions, reflecting increased production and adoption of solutions for ethanol and biodiesel." "We see that energy security is a theme. That people are pursuing sources other than oil. We have seen, among other things, that the blending ratio in fuel is shifting in many countries," says Rainer Lehmann. It is a matter of how much bioethanol is blended into regular fuel. For example, looking at the US, the sale of gasoline with a higher bioethanol content, E15, has been opened for the entire year this year. And Novonesis, which sells enzymes to American farmers for precisely ethanol production, is in the race to get farmers to choose the Danish company's enzymes for production. The proposal for permanent permission for nationwide year-round sales is to be voted on after the midterm elections. According to Haider Anjum, senior analyst at Jyske Bank, a potential expansion of E15 in the US is not yet factored into the group's long-term plans. He points out that it will be additional upside for sales. .\˙ MarketWire
- 5.11.Good earnings as expected
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 000 | ||
| 395 | ||
| 120 | ||
| 30 | ||
| 1 994 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 65 025 | 65 025 | 0 | 65 025 |
| Anonyymi | 569 822 | 569 822 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 65 025 | 65 025 | 0 | 65 025 |
| Anonyymi | 569 822 | 569 822 | 0 | 0 |
2026 Q3 - tulosraportti
UUTTA
6 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 20.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
2,35 DKK/osake
Viimeisin osinko
1,45%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·9 t sitten · MuokattuThere is a price potential of a full 30 % if the analysts are right......So hold on to your shares - we are going much higher up....... Novonesis target price raised after interim report 6 Nov. 07:46 ∙ News overview (AI) The Danish biotech company Novonesis (Novozymes) B experienced an increase in the share price following the publication of the company's latest interim report. In response to the financial results, a number of leading financial institutions have upgraded their target prices for the company. These widespread adjustments reflect strong analyst confidence, and several prominent banks reiterate positive recommendations such as 'Buy' or 'Overweight'. Novonesis (Novozymes) B shares rose 3 % on Nasdaq Copenhagen following the publication of the company's interim report. SEB and Nordea set the highest new target prices at respectively 580 DKK (up from 560 DKK) and 575 DKK (up from 540 DKK), and both maintain the 'Buy' recommendation. Barclays raised its target price to 510 DKK (from 500 DKK) with an 'Overweight' recommendation, while Danske Bank raised its target price to 465 DKK (from 455 DKK) with a 'Hold' recommendation. BNP Paribas raised its target price to 455 DKK (from 420 DKK) and maintains a 'Neutral' recommendation.The share price of Novonesis is not only lagging significantly behind the price of Givaudan. Compared to other peers such as DSM and Symrise, Novonesis also has a massive lag.
- 1 päivä sittenUnfortunate slump the last week. Was hoping that this would be a beneficiary of potential AI sector rotationIt will probably come back up, but it is a bit calmer than average, though it is way down now. However, it is a biotech stock whose potential for development is quite large with many branches out as well as acquisitions of small fry.
- ·1 päivä sittenGivaudan has delivered a reasonable return this year, both on share price and exchange rate. The price relation to Novonesis is interesting today. Rarely has the relative price of Novonesis been this low. Have therefore shifted Givaudan to Novonesis.
- ·6.11.Geopolitics is making customers seek other solutions, says Novonesis CFO Close today at 10:01 ∙ MarketWire Novonesis (Novozymes) B 4,51% Sky-high oil prices due to geopolitical unrest are causing many countries to seek alternative energy sources. And Novonesis plays a role here, as the group supplies enzymes used to make bioethanol. "We have not seen the big picture change in relation to our Bioenergy division. The activity level has increased - especially in emerging markets," says Novonesis CFO Rainer Lehmann to MarketWire. Here, the CFO specifically points to Asian countries, highlighting India, Indonesia, and Vietnam as drivers. Looking at total revenue in Asia Pacific in July, August, and September, it rose to 206.5 million euros compared to 193.4 million euros in the 2025 quarter. Emerging markets overall accounted for revenue of 437.3 million euros, up from 404.2 million euros in the third quarter of last year. DOUBLE-DIGIT GROWTH RATES IN ENERGY In the financial report, Novonesis writes that the energy division alone "was driven by double-digit growth in energy across most regions, reflecting increased production and adoption of solutions for ethanol and biodiesel." "We see that energy security is a theme. That people are pursuing sources other than oil. We have seen, among other things, that the blending ratio in fuel is shifting in many countries," says Rainer Lehmann. It is a matter of how much bioethanol is blended into regular fuel. For example, looking at the US, the sale of gasoline with a higher bioethanol content, E15, has been opened for the entire year this year. And Novonesis, which sells enzymes to American farmers for precisely ethanol production, is in the race to get farmers to choose the Danish company's enzymes for production. The proposal for permanent permission for nationwide year-round sales is to be voted on after the midterm elections. According to Haider Anjum, senior analyst at Jyske Bank, a potential expansion of E15 in the US is not yet factored into the group's long-term plans. He points out that it will be additional upside for sales. .\˙ MarketWire
- 5.11.Good earnings as expected
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 000 | ||
| 395 | ||
| 120 | ||
| 30 | ||
| 1 994 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 65 025 | 65 025 | 0 | 65 025 |
| Anonyymi | 569 822 | 569 822 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 65 025 | 65 025 | 0 | 65 025 |
| Anonyymi | 569 822 | 569 822 | 0 | 0 |